How I individualize frontline treatment for chronic-phase CML

Area of Science:

• Hematology
• Oncology
• Pharmacology

Background:

• Chronic myeloid leukemia (CML) treatment has advanced significantly with targeted therapies.
• BCR::ABL1 tyrosine kinase inhibitors (TKIs) are highly effective for newly diagnosed chronic phase CML.
• Current CML therapies offer excellent long-term survival, comparable to age-matched controls.

Purpose of the Study:

• To review the landscape of frontline targeted therapies for chronic myeloid leukemia.
• To discuss key factors influencing the choice of initial CML treatment.
• To highlight the importance of balancing efficacy with patient quality of life and treatment costs.

Main Methods:

• Review of existing literature on CML treatment guidelines and clinical trial data.
• Analysis of the efficacy, tolerability, and long-term outcomes of available BCR::ABL1 TKIs.
• Discussion of patient-centered factors in treatment selection.

Main Results:

• Five effective and well-tolerated BCR::ABL1 TKIs are available for newly diagnosed chronic phase CML.
• Long-term survival for CML patients is now excellent, approaching that of the general population.
• Lifelong treatment is typically required for most CML patients.

Conclusions:

• The selection of frontline CML therapy requires careful consideration of multiple factors beyond initial efficacy.
• Response durability, tolerability, quality of life, and toxicity avoidance are critical.
• Treatment administration ease and cost are increasingly important considerations for patients and healthcare systems.